We describe 3 patients with long-term parvovirus B19 infection (defined as detectable parvovirus B19 DNA load for 16 months after the onset of symptoms), which we monitored by serial testing for parvovirus B19 load and the presence of parvovirus B19-specific antibodies in blood. The patients showed recurrent erythema at intervals of several months.
Parvovirus B19 (hereafter, B19) infection can occur asymptomatically or with mild, nonspecific symptoms, but it can also lead to numerous acute diseases, such as erythema infectiosum (fifth disease), postinfectious arthropathies, transient aplastic crises in patients with hemolytic disorders, and fetal hydrops. B19 infection can sometimes persist, causing long-term or chronic conditions and illnesses, such as arthralgia and arthropathies (generally in adult female subjects), and chronic bone marrow failure and chronic anemias in immunocompromised patients [1] .
Cutaneous erythema is the main feature of erythema infectiosum and is the most prevalent manifestation of B19 infection in children. After a nonspecific prodromal illness that often goes unnoticed, the cutaneous rash appears first on the face ∼2 weeks after the acquisition of the infection. The often confluent maculopapular erythema on the cheeks and a relative perioral pallor create a "slapped cheeks" appearance. The subsequent eruption occurs 1-4 days later on the trunk and limbs and has a reticular or lacy pattern, consisting of pink maculae that usually undergo a central fading. The rash can then wax and wane for ∼3 weeks, reappearing because of different factors, such as exposure to sunlight and an increase in temperature. Because the rash occurs after the appearance of a specific im-mune response, it is assumed to be the result of immune complex deposition. In adults, dermal involvement by primary B19 infection is less frequent and uncharacteristic, and arthalgia and arthritis are the most common manifestations, affecting 60% of women and 30% of men with B19 infection [2] [3] [4] .
During the parvovirus B19 epidemic in Italy in 2002, a total of 162 subjects were found to be positive for B19 DNA. After the exclusion of children and immunocompromised patients (e.g., HIV-infected patients, transplant recipients, and patients with leukemia), 41 adult subjects agreed to have their blood tested at least once every month until the virus cleared and to report any B19-related symptoms. Of the 41 subjects, 9 experienced a long-term B19 infection (defined as a detectable B19 DNA load in serum for 16 months after the onset of symptoms [5] ). Among the 9 subjects with long-term B19 infection, 3 cases of recurrent erythema-with episodes separated by as much as several months-were identified and monitored by serial testing for B19 viral load and B19-specific IgM and IgG in the blood. The presence of B19 and the B19 viral load were determined by calibrated real-time PCR assay, as described elsewhere [6] . Levels of specific IgM and IgG against VP1+VP2 conformational epitopes were determined by EIA (Medac) [7] . Patient 1. A 35-year-old woman who was apparently immunocompetent was monitored for B19 infection markers for 13 months after the onset of B19-induced symmetrical arthritis that affected the elbows and the small joints of the hands (table  1) . At the beginning of the observation, no rash was observed; however, at months 2, 4, 7, and 10, an exanthem developed with the classic slapped cheek appearance. The facial exanthem lasted 2-3 days without involvement of the trunk and limbs. The rash did not coincide with sun or heat exposure or with the taking of hot baths. At month 9, arthralgias without rash were present, but, at month 10, the erythema was accompanied by arthralgias with painful and swollen joints of the hands. When erythema was present, B19 DNA was always detectable by PCR. B19-specific IgG was always present, but B19-specific IgM was found to be cleared at month 2 ,and B19-specific IgM was, therefore, not present during recurrences of the rash after that time.
Fever was always absent, and no anemia was observed. B19 was found to be cleared from the blood 11 months after the first blood sample was obtained; after the clearance of the virus, no reappearance of the rash was recorded during a 12-month follow-up period.
Patient 2. An apparently immunocompetent 45-year-old woman was monitored for B19 infection markers for 12 months after the onset of arthritis localized at the joints of the hands and wrists without rash (table 1) . The arthralgias lasted ∼70 days, and then a rash was observed at months 5 and 7 with the classic slapped cheek appearance on the face and with involvement of the limbs. In both instances, the exanthem lasted 3-4 days. The rash did not coincide with sun or heat exposure or with bathing in hot water. When erythema was present, B19 DNA was always detectable by PCR. B19-specific IgG was al-ways present, and B19-specific IgM was found to be cleared at month 5. The patient was always afebrile, and no anemia was observed. B19 had cleared from the blood 8 months after the first blood sample was obtained; after the clearance of the virus, there was no reoccurrence of the rash.
Patient 3.
A 24-year-old female nurse who was apparently immunocompetent was monitored for B19 infection markers for 12 months after the onset of classic fifth disease, which was characterized by fever and slapped cheek erythema, after exposure to a hospitalized child with B19 infection (table 1) . At months 2 and 4, very transient exanthems appeared, localized mostly on the trunk. The exanthem lasted only a few hours in each episode. The rash did not coincide with sun or heat exposure or with bathing in hot water. No arthralgias were reported. When the erythema was present, B19 DNA was always detectable by PCR. B19-specific IgG was always present, as was B19-specific IgM, during the rash episodes. B19-specific IgM cleared at month 10, and B19 DNA was undetectable after month 8. After the classic fifth disease had resolved, the patient was consistently afebrile, and no signs of anemia were observed.
Because B19 erythema can be clinically indistinguishable from other exanthems, in all 3 patients we excluded the presence of IgM and of IgG seroconversion specific for the main causes of infectious exanthems, such as rubella, measles, Epstein Barr virus, varicella-zoster virus, human herpesvirus 6, human herpesvirus 7, toxoplasmosis, and Borellia species. The patients denied exposure to potential environmental causes of rashes, such as biological contaminants (e.g., bacteria and fungi), chemical agents (e.g., cleaning products and pesticide residues), physical agents (e.g., fiberglass), insects (e.g., biting flies and moths), and allergens (e.g., dust mites).
Discussion. B19 infection is known to cause erythemas and arthralgias as a result of immune-complex deposition. Some long-term cases of B19-associated arthropathy and recurrent arthralgias that lasted a few months and, rarely, for years have been described, especially in adult women [2] [3] [4] . However, to our knowledge, long-term or recurrent rashes due to B19 infection have not been described as lasting for more than a few weeks after the onset of the first symptoms. During the B19 infection epidemic in Italy in 2002, we found 3 cases in adult women with a several-month history of recurrent B19-associated recurrent erythemas, which were diagnosed on the basis of the detection of B19 DNA, typical erythematous features, previous B19 infection, and potential exclusion of other causes of rash. The rashes lasted from a few hours to 2 weeks, appearing on the face, on the face and limbs, or on the trunk; they appeared to be self-limiting and were not attributable to a defined environmental exposure or to infectious agents other than B19. The patients with rash were afebrile and had no other associated signs or symptoms, apart from episodes of arthralgia.
The aim of the present report is to suggest the possibility that B19-associated rashes can be recurrent, even for many months after B19 infection has cleared. The search for B19-specific IgM is considered to be the gold standard for the diagnosis of erythema due to B19, but, in these recurrent cases, the diagnosis of B19 infection can be made mostly on the basis of the detection of B19 DNA alone, because, at the time of the appearance of recurrent rashes, B19-specific IgM may have already cleared.
In the present study, the 3 patients who experienced recurrent rashes were all adult women; school-aged children were not enrolled in this prospective study. However, we cannot rule out the possibility that the same feature could also occur in younger patients.
